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AbstrAct
There are numerous downstream consequences of marketed drugs like 
antineoplastic agents on the gut microbiome, an effect that is suggested to contribute 
to adverse event profiles and may also influence drug responses. In cancer, progress 
is needed toward modulation of the host microbiome to prevent off-target side 
effects of drugs such as gastrointestinal mucositis that result from gut dysbiosis. The 
objective of this study was evaluation of the bioactivity of a supplement consisting 
of capsules with a blend of 9 probiotic organisms of the genera Lactobacillus and 
Bifidobacterium plus 10 digestive enzymes, in protecting the human gastrointestinal 
tract from chemotherapy and an antibiotic. We used the Simulator of Human Intestinal 
Microbial Ecosystem (SHIME) model, an in vitro model of a stable colon microbiota, 
and introduced 5-fluorouracil (5-FU) and vancomycin as microbiome-disrupting drugs. 
The probiotic with digestive enzymes supplement, added in capsules at in vivo doses, 
improved fermentation activity in the colon reactors and accelerated the recovery of 
microbial populations following 5-FU/vancomycin treatment. The supplement restored 
the Bacteroidetes to Firmicutes ratios in the colon reactors, increased the diversity 
of microbiota, and induced the production of microbial metabolites that elicited anti-
inflammatory cytokines in an in vitro model of intestinal inflammation. In the proximal 
colon, preventative administration of the supplement resulted in full recovery of the 
gut microbial community after cessation of 5-FU and vancomycin treatment. These 
results identify a probiotic with digestive enzymes formulation that protects against 
drug-induced gut dysbiosis, highlighting its potential utility as a component of routine 
cancer care. 
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IntroductIon
The microbiome in the human gut is composed 
of 500–1000 distinct bacterial species and up to 1014 
total bacteria that are responsible for not only intestinal 
health but also for regulation of the immune system. 
The human gut microbiome is dominated by four main 
phyla: Firmicutes, Bacteroidetes, Actinobacteria, and 
Proteobacteria [1]. Metagenomic analyses show that 
changes in the relative abundance of the two dominant 
bacterial divisions, the Bacteroidetes and the Firmicutes, 
represent functional indicators of the metabolic potential 
of the gut microbiota, as demonstrated in experiments 
comparing microbiota in obese vs. lean animals [2]. 
Specifically, experiments have shown that obese mice had a 
50% reduction in Bacteroidetes and a proportional increase 
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in Firmicutes as compared to lean mice [3]. It is also 
interesting that this intestinal microbiota alteration in ratios 
of these phyla in obese subjects is associated with local and 
systemic inflammation [4]. Indeed, in the gut microbiome, 
the Bacteroidetes to Firmicutes ratio is regarded to be 
of significant relevance in diverse conditions that are 
associated with inflammation, including not only obesity 
[5], but also in aging [6], irritable bowel syndrome [7], 
and colon cancer [8]. In these cases, the decreased ratios 
of Bacteroidetes to Firmicutes were modulated in response 
to treatment strategies for example, by weight loss [5]. In 
another example, probiotic feeding was used to ameliorate 
the gut dysbiosis caused by a high-fat diet in experimental 
animals, marked by recovery of Bacteroidetes and a 
proportionate reduction in Firmicutes [9]. Of particular 
relevance to the present subject matter, colorectal cancer 
is marked by gut dysbiosis including reduced microbial 
diversity in the feces of patients than controls [1], and 
in tumor tissue compared vs. with areas of the mucosa 
at least 10 cm away [10]. Among other differences, a 
taxonomy based analysis of the gut microbiome showed 
that Firmicutes was significantly more abundant in the 
gut microbiota of cancerous tissues than that of adjacent 
non-cancerous tissues [11]. The mechanisms behind 
how these specific compositional changes in microbiota 
contribute to disease are not fully understood. The short-
chain fatty acids acetate and propionate are the main 
fermentation products of the Bacteroidetes phylum while 
butyrate is mainly produced by Firmicutes. However, 
despite the proportional increases in Firmicutes in colon 
cancer, butyrate concentrations, which functions in many 
contexts including mitigating inflammation, are decreased 
during colon carcinogenesis; therefore, it is possible that 
specific beneficial species within this phylum may be less 
predominant. Indeed, studies have shown that strains of 
Lactobacillus (Phylum: Firmicutes) and Bifidobacterium 
(Phylum: Actinobacteria) are diminished in colorectal 
cancer [1]. These common probiotic bacteria are lactate 
acid producers that are involved in anti-inflammatory 
responses, anti-cancer activity, and pathogen exclusion 
from gut colonization [1]. There is also a relationship 
between the lactic acid bacteria and the butyrate producers 
since the latter utilize lactate [12]. On this basis, there 
are numerous mechanisms by which gut microbiota 
dysbiosis leads to increased permeability, aberrant immune 
activation, and chronic inflammation, all of which can 
contribute to colorectal cancer initiation and progression 
[1]. This information raises the question as to whether 
specific probiotic formulations can be used to restore 
the microbial composition and the beneficial microbial 
metabolites in the gut
Intestinal microorganisms may determine the 
outcome of cancer treatments as well as being themselves 
affected by the treatments. Immunotherapeutic drugs, such 
as checkpoint inhibitor antibodies designed to unmask 
the cancer patient’s immune system, rely on a degree of 
endogenous immunity for their effectiveness, which is 
shown in several recent papers to be heavily influenced 
by the intestinal microbiome. For example, gut dysbiosis, 
evaluated based on stool samples, predicted resistance to 
immunotherapeutic interventions in melanoma patients 
[13]. Low diversity of commensal microorganisms 
was also associated with immune suppression in cancer 
patients [14]. Also, in a study of the anti-cancer effects of 
anti-PD1 or anti-PD-L1 checkpoint inhibitor antibodies, 
Bifidobacteria, a common probiotic strain, were found to 
be abundant in the colons of experimental animals that 
exhibited effective immunity against melanoma [15]. 
These lines of evidence provide testimony to the impact 
that the healthy gut microbiome has for cancer patients’ 
clinical outcomes. Specific therapeutics are also directly 
toxic to the gut microbiome and compromise patients’ 
recovery, notably, chemotherapeutic agents that can cause 
several side effects with gastrointestinal (GI) mucositis 
being one of the most frequent. Broadly speaking, 
chemotherapeutic agents cause changes in the microbiome 
that compromise energy metabolism, cause inflammation, 
and underlie the adverse events and poor quality of life of 
patients undergoing treatment. An example that has been 
studied is 5-fluorouracil (5-FU), first line agent for the 
treatment of metastatic colorectal agent, and a causative 
agent of severe colonic mucositis indicated by weight loss, 
diarrhea, bloody stool, shortened colon, and infiltration 
of inflammatory cells [16]. 5-FU diminishes bacterial 
richness and diversity in the gut, leading to reduced 
overall abundance of important phyla involved in normal 
microbial metabolism [16]. In fact, causal relationships 
are established between 5-FU-induced perturbations of the 
gut microbiota, the preponderance of pro-inflammatory 
cytokines in the intestinal milieu, and adverse events 
experienced by patients [16]. In another report that 
is of particular relevance to the present study, fecal 
microbiome transplantation was used to reverse antibiotic 
(ampicillin) and 5-FU-induced gut dysbiosis in a mouse 
model. Specifically, restoring the intestinal microbial 
composition to a healthy state by fecal microbiome 
transplantation successfully restored microbial diversity 
and richness, increased the composition of species known 
to exhibit anti-inflammatory actions such as Lactobacillus, 
and a coordinate reduction in known pathogenic strains 
[17]. Other drugs that are used in the armamentarium 
for cancer patients have also been proven to cause gut 
dysbiosis. Oral vancomycin, an antibiotic, is the mainstay 
of therapy for severe infections produced by Clostridium 
difficile, the most prevalent cause of healthcare-
associated infectious diarrhea in developed countries. 
In cancer patients, bacterial infections occur through 
diagnostic and therapeutic procedures, for example, due 
to placement of central venous catheters, and may have 
particularly serious consequences owing to the underlying 
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immunosuppression. During vancomycin therapy, most 
intestinal microbiota genera are depleted [18]. The 
rate of recovery of the microbiota following cessation 
from vancomycin determines whether the individual is 
subsequently susceptible to intestinal colonization by 
pathogenic bacteria. Since the duration of gut dysbiosis is a 
critical factor in managing adverse events of the treatment, 
evaluation of putative therapies such as probiotics should 
include monitoring the microbiota dynamics.
On the basis of this evidence, it has been widely 
suggested that modulation of the gut microbiome may 
be a useful therapeutic approach for improving the toxic 
side effects of cancer treatments, thereby possibly altering 
the trajectory of cancer. While a range or individual 
probiotic microorganisms or other supplements have 
been widely touted as having the capacity to modulate 
the gut microbiome, the challenge in the field has been 
the lack of validation of specific products. This is of 
particular significance for indications where patients are 
immunocompromised and undergoing treatment with 
cytotoxic agents since it has even been suggested that 
probiotics could induce bacteremia in certain populations 
[19–25]. Therefore, the potential utility of probiotic-
containing supplements for specific indications remains 
unleveraged as a preventative means for offsetting 
adverse events associated with cancer therapeutics and for 
improving patients’ outcomes.
To address the need for a probiotic formulation 
that protects against gut dysbiosis, this study evaluated a 
proprietary blend of 9 probiotic organisms of the genera 
Lactobacillus and Bifidobacterium, as well as 10 digestive 
enzymes, for its efficacy at protecting the gastrointestinal 
(GI) tract from the combined effects of 5-Fluorouracil 
(5-FU) and vancomycin. The probiotic with digestive 
enzymes supplement was evaluated using the Simulator 
of Human Intestinal Microbial Ecosystem (SHIME), 
a stable and reproducible in vitro system, to analyze its 
influence chemotherapy plus antibiotic-induced changes 
in microbial community activity and composition. The 
present experiments provided a very stringent test for 
the effects of this dietary supplement since the dysbiosis 
created in this system represented a “two-hit” system 
implementing two known microbiome-disrupting agents. 
We report that the probiotic with digestive enzymes 
supplement beneficially modulated the gut microbiome 
under healthy conditions, and, most significantly, 
improved recovery from 5-FU/vancomycin treatment 
when administered to the SHIME system. Improvements 
in microbial fermentation and attenuation of microbial 
community dysbiosis elicited by 5-FU/vancomycin were 
observed when the probiotic with digestive enzymes 
supplement was given in a curative context (i.e. beginning 
at the time of 5-FU/vancomycin treatment) but particularly 
when given in a preventative context (i.e. starting prior to 
5-FU/vancomycin). 
results
stability of the sHIMe system for analysis of 
the effects of a probiotic with digestive enzymes 
supplement
The SHIME in vitro model system was designed 
to create a stabilized microbiota community to allow 
for collection of samples from the different intestinal 
regions for analysis. Several microbial parameters were 
monitored throughout the SHIME experiment to assess 
the performance of the model and the basic changes in 
the microbial community composition and activity due to 
the probiotic with digestive enzymes supplement. After the 
first week during the stabilization period, reproducibility 
between each of the three SHIME units was determined 
in order to confirm initiation of preventive treatment in 
arm 3 of the SHIME. Reproducibility was confirmed 
by analysis of SCFA levels, which were 85.8% similar 
between the SHIME units. During the control period, 
stability and reproducibility of the other two SHIME 
units was determined. SCFA levels were stable within (on 
average 86.8% similar between consecutive time points in 
control period) and reproducible between the two SHIME 
units (on average 86.8% similar), clearly indicating 
stability and reproducibility of the microbial community 
in terms of activity and composition. On this basis, it was 
concluded that the effects that would be observed during 
the subsequent treatment period could be attributable to 
the probiotic with digestive enzymes supplement rather 
than due to variability in the system itself.
Modulation of acid/base consumption by the 
probiotic with digestive enzymes supplement 
that is indicative of increased fermentation 
activity
The consumption of acid and base reflects the 
overall microbial activity in the SHIME reactors 
representing the proximal and distal colon. Generally 
speaking, there are distinct bacterial populations that 
are native to the proximal and distal colon regions, 
reflecting the different requirements for digestion in each 
segment. Figure 1 depicts the average weekly acid/base 
consumption during the control and treatment periods (i.e. 
before and after 5-FU/vancomycin treatment). It should be 
noted that the treatment period consisted of one week of 
5-FU/vancomycin followed by three weeks without these 
agents during which time recovery from 5-FU/vancomycin 
could be monitored and compared for the experimental 
treatment arms, as follows: 1) Control arm: receiving no 
supplement; 2) Preventative arm that had already been 
receiving the probiotic with digestive enzymes supplement 
all through the previous stabilization and control periods; 
and. 3; The curative arm that commenced supplementation 
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with the probiotic with digestive enzymes supplement 
only at the start of 5-FU/vancomycin administration. 
As per Figure 1, 5-FU/vancomycin treatment 
caused significant changes in reducing base consumption 
the proximal colon but not the distal colon. In the 
proximal colon, the addition of the probiotics with 
digestive enzymes in both the curative and preventative 
treatment arms significantly increased base consumption 
in the proximal colon, countering the effects of 5-FU/
vancomycin. It should be noted that, in vivo, more bacterial 
fermentation activity also occurs in the proximal colon 
where substrate availability is higher [26]. In the distal 
colon, the probiotic with digestive enzymes supplement 
administered in the preventative arm also increased base 
consumption, however, the 5-FU/vancomycin itself did 
not significantly diminish this overall marker of metabolic 
activity in the distal colon reactors.
Improvements in short chain Fatty Acid (scFA) 
production by the probiotic with digestive 
enzymes supplement, revealing significant 
reversals of 5-Fu/vancomycin-associated changes
The abundant SCFA, acetate, propionate and 
butyrate, are generated by fermentation of dietary fibers by 
gut microbiota. SCFA have a plethora of health-promoting 
effects through their interactions with metabolite-sensing 
G protein-coupled receptors on the gut epithelium and on 
immune cells [27]. In these experiments, we monitored the 
production of these three SCFA in the proximal and distal 
colon reactors, comparing pre- and post-5-FU/vancomycin 
treatments in the control (non-supplemented), curative, 
and preventative arms that were treated with the probiotic 
with digestive enzymes supplement.
Figure 2 shows the results for acetate, which is 
produced by a range of gut microbes including Bacteroides 
and Bifidobacteria, and exerts anti-inflammatory effects 
[28]. Chemotherapy treatment resulted in a decrease 
in acetate levels in both the proximal and distal colon 
reactors. Although the recovery of acetate did not occur 
in the proximal colon, preventative treatment with the 
probiotic with digestive enzymes supplement increased 
acetate in both control and 5-FU/vancomycin treatment 
periods in the distal colon, suggesting that the pretreatment 
with the supplement offsets the adverse impact of the 
drugs on microbial metabolism.
In Figure 2, analysis of propionate concentrations 
in the SHIME is also provided, a product of a diverse 
group of metabolically active gut microbes, which 
exerts anti-inflammatory effects in the colon as well as 
systemically [28]. Once again, the expected reduction in 
propionate in the SHIME reactors was observed in the 
5-FU/vancomycin treatment period vs. the control period 
in both the proximal and distal colon reactors. Here, both 
the curative and preventative treatment arms with the 
probiotic with digestive enzymes supplement resulted in 
recovery of propionate levels relative to the control arm.
Figure 2 also shows the results for butyrate production 
in the SHIME reactors, a primary product of Clostridium 
clusters IV and XIVa (phylum Firmicutes). In vivo, butyrate 
is largely metabolized by intestinal epithelial cells where it 
serves as an energy source as well as a homeostatic factor 
for normal colonic cell turnover and repair processes 
[28]. In the SHIME, the expected result was obtained 
whereby 5-FU/vancomycin treatment strongly decreased 
butyrate levels in both the proximal and distal colon 
reactors. Supplementation of the reactors with curative and 
preventative administration of the probiotic with digestive 
Figure 1: the pH in the sHIMe system is maintained by pre-set pH controllers at 5.6–5.9 in the proximal colon (Pc) 
and at 6.6 to 6.9 in the distal colon (dc) to ensure optimal environments for microbiota. As the reactors acidify during 
changes in microbial activity, base is added. These results show acid and base consumption during control (c) and chemotherapy/antibiotic 
treatment (TR) periods for the control (CTRL), curative (CUR), and preventative (PREV) arms with the probiotic with digestive enzymes 
supplement. Results are shown for the reactors corresponding to the PC (A) and DC (b), and represent the average base/acid consumption 
over the entire control (n = 6 measurement) and treatment (n = 12) period. (*) represents statistically significant differences between C and 
TR (i.e. before and after 5-FU/vancomycin addition to the rea ctors, respectively). The different letters above the bars denote statistical 
comparisons between the indicated groups where uppercase or lowercase letters define distinct comparator groups; p < 0.05 was considered 
significant. 
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enzymes supplement resulted in improved butyrate 
production in the proximal and distal colon. Notably, the 
differences between the curative and preventative arms were 
not statistically different in either of the reactors. 
changes in gut microbiota by the probiotic with 
digestive enzymes supplement, revealing an 
effect in countering 5-Fu/vancomycin-induced 
gut dysbiosis
To further evaluate the impact of the probiotic 
with digestive enzymes supplement, the next series 
of experiments utilized qPCR to identify changes the 
microbial composition in the SHIME reactors representing 
the proximal and distal colon. These analyses focused on 
looking at the rates of recovery of healthy microbiota 
following the administration of 5-FU/vancomycin during 
treatment week 1 (TR1; refer to Figures 3 and 4), where 
5-FU/vancomycin was discontinued during the recovery 
weeks spanning TR2-TR4 (Figures 3 and 4). Comparisons 
were also conducted relative to the control period of the 
SHIME where no 5-FU/vancomycin had been added but 
the preventative arm was already receiving the probiotic 
with digestive enzymes supplement, allowing its influence 
on a healthy microbiome to be evaluated. 
Specific strains of Lactobacillus and Bifidobacterium 
strains exert beneficial influences on maintenance of 
integrity of intestinal tissue in inflammatory circumstances 
Figure 2: effect of curative and preventative administration of a probiotic with digestive enzymes supplement on 
short chain fatty acid production in sHIMe reactors corresponding to the proximal colon and distal colon. Average 
acetate, propionate, and butyrate production, as indicated, over the control (C) (n = 6) and treatment (TR) (n = 12) periods for the control 
(CTRL), curative (CUR), and preventative (PREV) arms given the probiotic with digestive enzymes supplement is presented. (*) represents 
statistically significant difference relative to the preceding period. The different letters above the bars denote statistical comparisons 
between the indicated groups where uppercase or lowercase letters are used to delineate the distinct comparator groups, and p < 0.05 was 
interpreted as significant.
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and actions against toxicity of chemotherapeutic agents 
including intestinal mucositis [29–33]. In addition to being 
permanent genera of the human intestinal microbiota, 
these strains are highly enriched in the probiotic plus 
digestive enzymes supplement. We evaluated the SHIME 
reactors for the presence of these lactate-producing 
bacteria, the Lactobacillus and Bifidobacterium strains. In 
Figure 3, data are shown for control and 5-FU/vancomycin 
treatments among the different experimental arms that 
received no supplement or either curative or preventative 
administration of the probiotic with digestive enzymes 
supplement. First, as we expected, the results showed 
that 5-FU/vancomycin reduced the populations of these 
bacteria in the SHIME. For Lactobacillus, after the 5-FU/
vancomycin treatment period during TR1 (Figure 3), 
Lactobacillus levels recovered after administration of the 
probiotic with digestive enzymes supplement, but also for 
the negative control in both colon regions. Significantly 
however, treatment with the supplement resulted in a 
faster recovery as compared to the negative control that 
lacked the supplement (Figure 3). For Bifidobacteria, 
after cessation of 5-FU/vancomycin, the levels of these 
microbes dropped drastically for the negative control 
in both colon regions, but especially in the PC where 
Bifidobacteria levels dropped below detection limit at 
the end of the treatment period (Figure 3). Administration 
of the probiotic with digestive enzymes supplement 
resulted in a slight recovery of Bifidobacteria levels, 
with no differences observed between the curative and 
the preventive arms of supplementation. It should be 
noted that, during the control periods (C1 and C2) prior 
to 5-FU/vancomycin treatment, overall Lactobacilli and 
Bifidobacteria did not increase in the PC or the DC. 
We also assessed the composition of Bacteroidetes 
and Firmicutes, the predominant phyla in the healthy human 
gut, to determine how they are influenced by the probiotic 
with digestive enzymes supplement in the SHIME. The 
results showed that Bacteroidetes levels were particularly 
depleted during the 5-FU/vancomycin treatment period. 
Significantly, we observed that administration of the 
probiotic with digestive enzymes supplement also 
resulted in faster recovery of Bacteroidetes after 5-FU/
Figure 3: Analysis of modulation of the Lactobacillus and Bifidobacterium composition by the probiotic with digestive 
enzymes supplement. The effect of a curative (CUR) and preventive (PREV) administration of the probiotic with digestive enzymes 
supplement as compared to a control SHIME (CTRL) on luminal Lactobacillus (left panels) and Bifidobacterium (right panels) levels (16S 
rDNA copies/mL) in the proximal (PC; top panels) and distal colon (DC; bottom panels). The data are represented for the control weeks 
(C1, C2) and treatment weeks (TR1, TR2, TR3, and TR4. It should be noted that 5-FU/vancomycin was administered to the system in TR1 
and discontinued in TR2–TR4. Preventative administration of the probiotic with digestive enzymes supplement was being administered 
throughout the control periods (C1 and C2), while curative supplementation of the probiotic with digestive enzymes formulation was 
initiated and maintained at TR1-TR4. (*) indicates statistically significant differences relative to the preceding period, while different letters 
indicate a statistical difference between different treatments; p < 0.05.
Oncotarget30925www.oncotarget.com
vancomycin (after TR1) as compared to the control arm, 
an effect that was the greatest for the preventative arm 
of supplementation over the curative arm (Figure 4). 
Remarkably, the Bacteroidetes levels were restored to 
control (pre-5-FU/vancomycin) levels during treatment 
weeks 3 and 4. This finding supports the capacity of the 
supplement to hasten the recovery of the gut microbiota 
following 5-FU/vancomycin treatment with the lowest 
levels observed in the colon reactors on treatment week 2 
(TR2; Figure 4). Analysis of Firmicutes showed a more 
modest depletion in response to 5-FU/vancomycin that 
was evident at treatment week 1 (Figure 4), however, all 
three arms (control, preventative, and curative) recovered 
in the colon reactors after the treatment was discontinued. 
Interestingly, as can be appreciated in the proximal colon 
reactors, there was a faster recovery of Firmicutes in 
the preventative and curative arms vs. the control arm. 
This recovery was noted during TR2 and TR3 where the 
probiotic with digestive enzymes supplement promoted 
the rapid return to the Firmicutes levels in the control 
period. Overall, these results show that the probiotic and 
digestive enzymes supplement restores the Bacteroidetes to 
Firmicutes ratios following 5-FU/vancomycin. 
Increased diversity of the microbial community 
is promoted by administration of the probiotic 
with digestive enzymes supplement
16S-targeted Illumina sequencing was used whereby 
amplified 16S rRNA marker gene sequences are clustered 
into taxonomic units of bacteria. When the data had 
been processed at the phylum and family levels, and 
the Simpson diversity index was calculated. The lowest 
possible value of the index is 1, representing a community 
consisting of only one Operational Taxonomic Unit 
(OTU). The highest possible value is the total number of 
OTUs, and the higher the index, the larger the diversity 
and the larger the evenness. Table 1 shows the Simpson 
Diversity Index results to evaluate the impact of the 
probiotic with digestive enzymes supplement on diversity 
changes in the microbiota in the SHIME that are caused by 
5-FU and vancomycin. In the distal colon, the supplement 
Figure 4: changes in the dominant phyla of beneficial gut microbes, bacteriodetes and Firmicutes, by the probiotic 
with digestive enzymes supplement. The effect of a curative (CUR) and preventive (PREV) administration of the probiotic with 
digestive enzymes supplement as compared to a control SHIME (CTRL) on luminal Bacteroidetes, and Firmicutes levels (16S rDNA 
copies/mL) in the proximal (PC; top panels) and distal colon (DC; bottom panels). The data are represented for the control weeks (C1, 
C2) and treatment weeks (TR1, TR2, TR3, and TR4. It should be noted that 5-FU/vancomycin was administered to the system in TR1 
and discontinued in TR2-TR4. Preventative administration of the probiotic with digestive enzymes supplement was being administered 
throughout the control periods (C1 and C2), while curative supplementation of the probiotic with digestive enzymes formulation was 
initiated and maintained at TR1-TR4. (*) indicates statistically significant differences relative to the preceding period, while different letters 
indicate a statistical difference between different treatments; p < 0.05.
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given preventatively had the most significant impact 
on increasing the microbial diversity. In the proximal 
colon, the highest diversity was observed in the negative 
control (i.e. no supplement) following recovery from 
5-FU and vancomycin (TR4). Curative treatment with the 
supplement also increased the microbial diversity in both 
the proximal and distal colons. 
Lastly, 16S-targeted Illumina sequencing was used 
to evaluate the differences in microbial compositions at 
the phylum level in the proximal and distal colons caused 
by the probiotic with digestive enzymes supplement. 
In Figure 5, the results show that the supplement did 
indeed cause changes in the microbial communities. The 
preventative treatment prior to 5-FU/vancomycin treatment 
did not cause any major changes at the phylum level in the 
proximal colon. However, in the distal colon, preventative 
supplementation resulted in increases in abundance 
of Actinobacteria and reductions in Bacteroidetes and 
Proteobacteria.
Following 5-FU/vancomycin treatment, the 
microbiome in the distal colon did not differ at the 
phylum level for the control, curative or preventative arms 
Figure 5: Addition of the probiotic with digestive enzymes supplement to the sHIMe modulates the microbial 
communities at the phylum level. Abundance (%) of the dominant phyla in the lumen of the proximal (PC) and distal colon (DC) of 
the SHIME upon a curative (CUR) and preventive (PREV) administration of the probiotic with digestive enzymes supplement as compared 
to control (CTRL) the end of the control week 2 (C) and treatment week 4 (TR) period. 
table 1: changes in the diversity of microbiota resulting from curative or preventative administration of the probiotic 
with digestive enzymes supplement
control curative Preventative
control treatment control treatment control treatment
Proximal Colon 3.0 7.6 2.7 5.4 2.2 2.6
Distal Colon 7.5 7.5 7.5 9.2 11.5 11.2
Reciprocal Simpson Diversity Index in the lumen of the proximal and distal colon of the SHIME upon a curative (CUR) and 
preventive (PREV) administration of the probiotic with digestive enzymes supplement was compared to a control SHIME 
(CTRL) at the end of the control [control week 2 (C)] and treatment [treatment week 4 (TR4)] periods. The intensity of the 
shading indicates the absolute diversity index, normalized for each of the environments (i.e. within each row).
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(Figure 5). In contrast, in the proximal colon, only 
preventive administration of the probiotic with digestive 
enzymes supplement resulted in full recovery of the gut 
microbiota after cessation of 5-FU/vancomycin treatment, 
mainly increasing the abundance of Bacteroidetes at 
the expense of Proteobacteria as compared to the other 
experimental arms. Collectively, these findings support 
the most significant changes in beneficial microbial 
communities as occurring in response to preventative 
administration with the probiotic with digestive enzymes 
supplement. However, it is plausible that a longer duration 
of curative treatment with the supplement would afford 
similar results as the preventative treatment.
Impact of the probiotic with digestive enzymes 
supplement on cytokines in an in vitro model of 
intestinal inflammation
We next asked how the probiotic with digestive 
enzymes supplement alters the composition of bacterial-
derived metabolites having the potential to impact immune 
function as a means of offsetting the negative effects of 
5-FU/vancomycin. To this end, we leveraged an in vitro 
model system that has been described as an ‘inflammatory 
bowel disease-like’ model that uses Caco-2 (intestinal 
epithelial like cells) and THP-1 macrophages [34]. Caco-2 
cells originate from a human colon adenocarcinoma cell 
line that can differentiate into mature, enterocyte-like cells 
that are characterized by the formation of villi, presence 
of tight junctions, and expression of apical brush border 
enzymes, thereby recapitulating the colon [35]. THP-1 
cells, derived from acute leukemia, differentiate into 
macrophages upon culture with phorbol 12-myristate 
13-acetate (PMA), and can then be activated toward a 
highly pro-inflammatory phenotype upon treatment with 
lipopolysaccharide (LPS). In the setup used here, Caco-2 
cells were placed on top of PMA-treated THP-1 cells, 
on the apical and basolateral sides of culture chambers, 
respectively. Colonic suspensions collected from the 
SHIME reactors, treated with the same regimens of 
5-FU/vancomycin and probiotic with digestive enzymes 
supplement as in the previous experiments, were added to 
the apical side of the culture chambers containing Caco-2 
cells. After 24 h of the apical pre-treatment of the Caco-2/
THP-1 co-cultures with the SHIME samples, the basolateral 
supernatant was discarded and the THP cells were treated 
with LPS to provide inflammatory signals. Subsequently, 
after 6 hours of stimulation, cytokines were measured 
from the basolateral side of the chamber containing the 
THP-1 cells, which will have been affected indirectly by 
signals from the Caco-2 cells or directly by the transport of 
metabolites and molecules. In this manner, the interactions 
between cells of the gut and the immune system can be 
recapitulated in vitro. These experiments allow examination 
of the influence of the microbial fermentations-derived 
products following preventive and curative administration 
of the probiotic with digestive enzymes supplement in the 
face of 5-FU/vancomycin treatment.
The results of the Caco-2/THP-1 co-culture 
experiments are provided in Figure 6. Measurement 
of IL-6 was performed as known pro-inflammatory 
signature of LPS-stimulated macrophages, and also of 
colonic mucosal cells [36, 37]. The results showed that 
preventative treatment with the probiotic with digestive 
enzymes supplement generated microbial metabolites 
in the proximal colon reactors that decreased IL-6 
concentrations in the co-culture model as compared 
to the control reactors that were not supplemented but 
were treated with 5-FU/vancomycin. Thus, LPS-induced 
inflammation was modulated by fermentation products 
derived from reactors to which the supplement was 
administered prior to treatment with 5-FU/vancomycin. 
From the distal colon reactors, the SHIME suspensions 
taken from the control period, during which baseline 
microbial activities were monitored, and the treatment 
period with 5-FU/vancomycin did not differ with respect 
to the concentrations of IL-6 in the co-culture. Secondly, 
we also monitored IL-10 production induced in the Caco-
2/THP-1 cultures as a representative anti-inflammatory 
cytokine produced by macrophages during LPS 
stimulation (Figure 6). One point of interest was that that 
the metabolites from SHIME reactors following treatment 
with 5-FU/vancomycin induced greater IL-10 production 
than those from the control (baseline) period in the PC. 
However, administration of the probiotic with digestive 
enzymes supplement prior to 5-FU/vancomycin (i.e the 
control period) generated metabolites in the PC with the 
highest IL-10 inducing capabilities in the co-cultures. 
In the DC, the results showed statistically significant 
increases in IL-10 were generated in co-cultures given 
SHIME suspensions from the preventative arm from 
both the control period and 5-FU/vancomycin treatment 
period. Collectively, the reductions in IL-6 and increases 
in IL-10 observed in the Caco-2/THP-1 model of intestinal 
inflammation containing SHIME suspensions suggest that 
the probiotics with digestive enzymes supplement affects 
the gut microbiome toward controlling inflammation.
dIscussIon
The objective of this study was to evaluate the 
potential benefits of a proprietary probiotic with digestive 
enzymes supplement in preventing the gut dysbiosis 
caused a chemotherapy treatment and an antibiotic in a pre-
clinical analysis of bioactivity. The test product contains 
a blend of 9 probiotic organisms of the Lactobacillus and 
Bifidobacterium genera, as well as 10 digestive enzymes 
contained in capsules that were administered in an in vitro 
system to recapitulate the gut microbiome using doses of 
the product that would be administered clinically. Using 
the SHIME model platform, where the gut microbiota can 
be cultured under representative conditions of the different 
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intestinal regions, we successfully demonstrated that the 
probiotic with digestive enzymes supplement was capable 
of modulating the effects of 5-FU/vancomycin when 
administered in a preventative context. We also noticed 
positive changes in the microbial activity and composition 
using the probiotic with digestive enzymes supplement 
added to the SHIME beginning at the same time as 
5-FU/vancomycin (i.e. the curative arm), including the 
production of metabolites that induced anti-inflammatory 
cytokine production in the Caco-2/THP-1 model. Based on 
studies that are ongoing, we believe that a longer duration 
of curative supplementation than was performed in the 
SHIME would have achieved at least a similar magnitude 
of beneficial effects as the preventative arm. 
The present study bridges the large gap that exists 
between the extensive microbiome research taking place 
and the lack of validation for specific products that are 
on the market. To this point, one DNA-based analysis of 
bifidobacterial species in commercial probiotic products 
demonstrated that only one of sixteen tested products 
matched the bifidobacterial label claim, and pill-to-pill 
and lot-to-lot variation was observed [38]. The authors of 
this study also pointed out that misidentified commercial 
products, in addition to the lack of comparison between 
strains or species, is a barrier to the ability of clinicians 
to make informed decisions about what to prescribe. 
Another point of discussion is that there is a great deal 
of variability between products in terms of how many 
viable, functional probiotic bacteria can be delivered to 
the gut; therefore, testing of effectiveness of supplements 
using advanced in vitro analysis is advisable [39]. Another 
understudied area, which, to our knowledge, has not 
been previously examined in pre-clinical studies, is a 
supplement that combines probiotic microorganisms with 
digestive enzymes. While digestive enzymes generally 
serve to improve nutrient absorption in the gut, they also 
Figure 6: Modulation of cytokine profiles in an in vitro model of intestinal inflammation by metabolites from sHIMe 
reactors treated with the probiotic with digestive enzymes supplement. Samples of SHIME suspensions were taken from 
reactors with curative (CUR) and preventive (PREV) administration of the probiotic with digestive enzymes supplement as compared to a 
control SHIME (CTRL; no supplement) from the control period (baseline microbial community prior to 5-FU/vancomycin) and treatment 
period with 5-FU/vancomycin. Cytokine levels of IL-6 (A) and IL-10 (B) were measured 6 h after LPS treatment on the basolateral side 
of the Caco2/THP-1 co-cultures after pre-treatment of the apical side for 24 h with the SHIME samples. The red dotted line corresponds 
to the experimental control consisting of LPS. Data are plotted as the mean ± SEM. The chart (lower panel) outlines the corresponding 
statistical analyses performed using two-way ANOVA with Dunnett’s multiple comparisons test. Significance is depicted where (*). (*), (**), 
(***) and (****) represent p < 0.05, p < 0.01, p < 0.001 and p < 0.0001, respectively. Ns = non-specific; PC: proximal colon; DC: distal colon.
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are expected to have a complementary or synergistic 
role with the probiotic microbes. One study reported 
that pancreatic enzyme supplementation to experimental 
animals modified the intestinal microbiota, allowing 
increased colonization of Lactobacillus strains in addition 
to improving nutritional status [40]. In a study related 
to microbial activities in the genital tract, amylase, a 
glycogen-degrading enzyme, was found to allow for the 
growth of certain Lactobacillus isolates in the glycogen 
breakdown products that cannot grow in absence of the 
enzyme [41]. These studies support a beneficial impact of 
combining probiotics with digestive enzymes to improve 
microbial metabolism in the gut.
Cancer patients undergoing chemotherapy, radiation 
therapy or other drug treatments experience a plethora of 
adverse events related to their treatments including nausea, 
vomiting, diarrhea, and loss of appetite, leading to a lower 
dietary intake, weight loss, and susceptibility to infections. 
These symptoms can be directly linked to the disturbed 
intestinal microbiome. During gut dysbiosis, parameters 
such as water volume, ion concentrations, osmotic 
pressure and pH are often abnormal, leading to growth of 
bacteria that further contribute to homeostatic imbalances 
and mediate aggressive inflammation [42]. This 
inflammation damages the intestinal mucosa, reducing 
the overall microbial diversity and allowing pathogenic 
species to thrive in the gut. Indeed, pyrosequencing 
studies have demonstrated that probiotics can afford a 
5-fold decrease in the abundance of members of the genus 
Fusobacterium [43], potential pathogens that are enriched 
in the mucosal flora of colorectal cancer patients [44]. By 
introducing missing microbial components, probiotics 
are believed to directly antagonize enteric pathogens, 
modulate innate or adaptive immunity, and strengthen 
mucosal barrier function to alleviate gastrointestinal 
symptoms [45]. Cancer cachexia, a metabolic disorder 
characterized by anorexia and muscle wasting, represents 
another unmet medical need. Interestingly, in an animal 
model of leukemia that is characterized by cachexia, 
administration of an oral probiotic to restore Lactobacillus 
species reduced the expression of markers of atrophy in the 
muscles as well as inflammatory cytokines including IL-6 
[46]. Similarly, administration of prebiotics in a cachexia 
model led to modulation of the gut microbiome, including 
increases in beneficial strains such as Bifidobacterium, 
which coincided with metabolic shifts in the periphery 
and a delay in tumor-induced cachexia [47]. Conservation 
of the gut microbiome may therefore improve not only 
tumor- and treatment-associated changes the gut itself but 
also systemic metabolic disturbances.
A separate and related issue is the role of the gut 
microbiome in tumor initiation since there is abundant 
evidence that chronic infection and the ensuing inflammation 
are contributing factors to tumor initiation [48]. SCFA 
promotes and maintains colonic epithelial health through 
maintaining barrier function, suppressing tumorigenesis by 
regulating DNA methylation and diminishing oxidative stress, 
and inhibiting inflammation (Sun) It is plausible that dietary 
changes or probiotic interventions may reduce the risk of 
colorectal cancer, however, the potential impact of microbiome 
modulating-strategies on tumorigenesis itself is not clear, and 
awaits investigation for the probiotics with digestive enzymes 
supplement that was the focus of the current study.
The limited evidence confirming the safety and 
benefits of these products in human clinical studies has 
led to a recommendation for cancer patients, who are 
immunocompromised, to take only moderate doses of 
dietary supplements or none at all [49]. Isolated case 
reports have asserted that overt bacteremia can result from 
the use of probiotics by immunocompromised patients. 
Several cases of Lactobacillus and Bifidobacterium 
bacteremia [19–25] as well as cases of sepsis associated 
with Saccharomyces cerevisiae [50, 51], a probiotic strain 
used the treatment and prevention of Clostridium difficile-
associated diarrhea, have been reported to be associated 
with probiotic intake by ICU patients and individuals 
with immunodeficiency disorders. The amassed results 
from 17 studies revealed 5 case reports of probiotic-
associated bacteremia or fungaemia based on blood culture 
tests. Another analysis [52] concluded that “there remain 
insufficient studies to assess the true effect of probiotics 
in people with cancer. Meta-analysis suggests probiotics 
may be beneficial but further studies are still required. 
Improved reporting of outcomes and adverse events 
in clinical trials are required to improve accuracy and 
confidence of conclusions drawn in future updates.” With 
respect to efficacy, another a recent meta-analysis carried 
out to analyze data related to the efficacy and safety of 
probiotics in people with cancer, the results compiled for 
11 studies showed that probiotics may reduce the severity 
and frequency of diarrhea in patients with cancer and may 
reduce the requirement for anti-diarrheal medication, 
however, the analysis showed that firm conclusions could 
not be drawn with the available information [53]. We would 
argue, and it is our approach, that research and clinical 
studies need to be performed in a product-specific manner 
to evaluate for a positive impact on the microbiome and for 
efficacy for a particular indication. In sum, using a dynamic 
model of the gut ecosystem, this report validates a probiotic 
with digestive enzymes supplement as being beneficial for 
countering microbial imbalances and maladaptation in the 
gastrointestinal tract. These results provide an impetus for 
clinical studies evaluating the curative and preventative 
effects of this supplement against chemotherapy-associated 
adverse events that stem from gut dysbiosis.
MAterIAls And MetHods
Probiotic with digestive enzymes supplement
The probiotic with digestive enzymes supplement 
used herein comprises capsules is manufactured using 
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proprietary methods and contains a blends of probiotics 
(116.20 mg total weight); specifically, Bifidobacterium 
infantis, Bifidobacterium bifidum, Lactobacillus 
acidophilus, Lactobacillus salivarius, Lactobacillus 
plantarum, Lactobacillus rhamnosus, Bifidobacterium 
longum, Lactobacillus casei, Lactobacillus paracasei, and 
digestive enzymes (272.65 mg total weight); specifically, 
amylase, glucoamylase, lipase, bromelain, maltase, 
lactase, hemicellulose, xylanase, papain, and invertase. 
The capsules used herein are the same formulation 
that would be administered in vivo. The product was 
tested at an in vitro dose of 3 capsules/day before 
chemotherapy/antibiotic treatments, and 4 capsules/day 
during and after chemotherapy/antibiotic treatment (to be 
described below). This corresponds to an in vivo dosage 
of 6 capsules/day and 8 capsules/day before and after 
chemotherapy/antibiotic treatment, respectively.
simulator of human intestinal microbial 
ecosystem (sHIMe) setup 
ProDigest (Gent, Belgium) conducted the SHIME 
experiments and analysis. Briefly, the SHIME system 
consists of a series of double-jacketed vessels, simulating 
the digestive compartments that are initially inoculated 
with a fecal sample from a healthy adult donor using 
methods described previously [54].
The typical reactor setup consists of a succession 
of five reactors simulating the different parts of the 
human gastrointestinal tract. The first two reactors 
simulate different steps in food uptake and digestion, with 
peristaltic pumps adding a defined amount of SHIME feed 
(140 mL 3×/day) and pancreatic and bile liquid (60 mL 3×/
day), respectively to the stomach (V1) and small intestine 
(V2) compartment and emptying the respective reactors 
after specified intervals [54]. The last three compartments 
simulate the large intestine. These reactors are continuously 
stirred, and they have a constant volume and pH control. 
Retention time and pH of the different vessels are chosen 
in order to resemble in vivo conditions in the different parts 
of the colon. Upon inoculation with fecal microbiota, these 
reactors simulate the ascending (V3), transverse (V4) and 
descending (V5) colon. 
The present experiments employed an adapted 
SHIME setup to accommodate the following three 
treatment arms (vs. two arms that are typically compared 
using this system):
Control Arm: Chemotherapy and antibiotics; no 
supplement given.
Curative Arm: Chemotherapy and antibiotics; 
probiotic with digestive enzymes supplement added at the 
same time as the other agents.
Preventative Arm: Chemotherapy and antibiotics; 
probiotic with digestive enzymes supplement added prior 
to the other agents.
Accordingly, a TripleSHIME set-up was utilized 
wherein the colon reactors were limited to two instead 
of three to account for the additional test conditions 
required; specifically, reactors corresponding to PC-DC 
units (proximal and descending colon) instead of AC-
TC-DC units (ascending, transverse, and descending 
colon). 
stages of the sHIMe experiment
The stages of the experiment are described below 
and also summarized in Table 2.
stabilization period (Weeks 1 and 2)
After inoculation of the colon reactors with an 
appropriate fecal sample, a two-week stabilization period 
allowed the microbial community to differentiate in the 
different reactors depending on the local environmental 
conditions. During this period, the basic nutritional matrix 
was provided to the SHIME to support diversity of the gut 
microbiota originally present in the fecal inoculum. The 
third arm of the SHIME setup (preventive arm; PREV), 
already received 3 capsules/day during the stabilization 
period (corresponding to an in vivo dose of 6 capsules/day).
control period (Weeks 3 and 4)
During this two-week reference period, the standard 
SHIME nutrient matrix was further dosed to the model. 
Analysis of samples in this period allows to determine the 
baseline microbial community composition and activity in 
the different reactors, which will be used as a reference 
for evaluating the treatment effects. The third arm of the 
SHIME setup (PREV), already received 3 capsules/day 
during the control period (~ in vivo dose of 6 capsules/
day).
treatment period (Weeks 5–8; 5-Fu plus vancomycin 
during Week 5)
During this four-week period, the SHIME reactor 
was operated under nominal conditions, but each arm was 
treated as follows. During the first week, all arms received 
chemotherapy (10 μM of 5-fluorouracil (5-FU)) and 
vancomycin treatment (62.5 mg/L of vancomycin). During 
the subsequent weeks, it was considered a “recovery” 
period from the effects of 5-FU and vancomycin. Arm 1 
of the SHIME did not receive any additional treatment (i.e. 
control arm; CTRL). Arm 2 of the SHIME received the 
probiotic with digestive enzymes supplement (4 capsules/
day ~ in vivo dose of 8 capsules/day) at the start of the 
chemotherapy administration (i.e. curative arm; CUR), 
whereas addition of the supplement for arm 3 of the 
SHIME was continued (at 4 capsules/day ~ in vivo dose of 
8 capsules/day) (PREV).
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Analysis of the activity and composition of 
microbiota in the sHIMe
The following microbial parameters were monitored 
throughout the entire SHIME experiment to evaluate the 
performance of the model and/or to allow monitoring of 
basic changes in the microbial community composition 
and activity due to the probiotic with digestive enzymes 
supplement.
Microbial community activity
The concentrations of SFCA; specifically, acetic 
acid, propionic acid and butyric acid, were analyzed as 
by-products of microbial metabolism. Each of these 
parameters was measured three times/week. Briefly, SCFA 
were extracted from samples with diethyl ether after the 
addition of 2-methylhexanoic acid as an internal standard. 
Extracts were analyzed using gas chromatography as 
described previously [55]. The concentrations of lactate, 
the precursor of SCFA, were also monitored using a 
d-lactate/l-lactate kit (R-Biopharm, Mannheim, Germany), 
according to the manufacturer’s protocols. 
Microbial community composition
As part of the SHIME experiments, the following 
groups were quantified via quantitative PCR (qPCR; 
once/week): Bacteroidetes phylum, Firmicutes phylum, 
Lactobacillus spp. and Bifidobacterium spp. as previously 
reported [56]. 
16s-targeted Illumina sequencing 
16S ribosomal RNA (rRNA) sequencing was used 
to analyze samples from the SHIME reactors to identify 
and compare the microorganisms using similar methods 
as published elsewhere [57]. The Illumina sequencing 
method was used to amplify microbial sequences until 
a saturation level was reached. Information on a broad 
spectrum of OTUs was obtained (>100 different of 
the most dominant OTUs), however, the results were 
presented as proportional values versus the total amount 
of sequences within each sample, thus providing semi-
quantitative results. The methodology used primers that 
span 2 hypervariable regions (V3–V4) of the 16S rDNA. 
Using a paired sequencing approach, sequencing of 2×250 
bp resulted in 424 bp amplicons.
To provide an ecological interpretation of these data, 
the Simpson reciprocal index was calculated as a measure 
of diversity and evenness of the microbiota as described 
previously [58]. An increase in the Simpson reciprocal 
index reflects a diversity increase, with 1 being the lowest 
possible number, and the number of bacterial species/
OTUs present in the sample being the maximal number. 
The index will approach the maximal value when the OTU 
distribution is more even. The higher the index, the larger 
the diversity and the larger the evenness.
In vitro analyses of immune markers
caco-2 cells
The co-culture experiment was performed as 
previously described [34] Briefly, Caco-2 cells (HTB-37; 
American Type Culture Collection) were seeded in 24-well 
semi-permeable inserts (0.4 μm pore size) at a density of 
1 × 105 cells/insert. Caco-2 monolayers were cultured 
for 14 days, with three medium changes/week, until 
a functional cell monolayer was obtained. Cells were 
maintained in Dulbecco’s Modified Eagle Medium 
(DMEM) containing 25 mM glucose and 4 mM glutamine 
and supplemented with 10 mM HEPES and 20% (v/v) 
heat-inactivated (HI) fetal bovine serum (FBS).
tHP-1 cells
THP1 cells (InvivoGen) were maintained in Roswell 
Park Memorial Institute (RPMI) 1640 medium containing 
11 mM glucose and 2 mM glutamine, supplemented with 
10 mM HEPES, 1 mM sodium pyruvate and 10% (v/v) 
HI-FBS. THP1 cells were seeded in 24-well plates at a 
density of 5 × 105 cells/well and treated with 100 ng/mL 
of PMA for 48 hours (h). PMA induces the differentiation 
of the cells into macrophage-like cells.
caco-2/tHP-1 co-cultures
To mimic the interface between host immune cells 
and the fermentation products of the gut microbiome, 
in vitro experiments were conducted based on previous 
studies by Satsu and colleagues [59]. In this setup, the 
colonic suspensions collected from the SHIME are 
brought in contact with the apical side of the co-cultures 
(i.e. Caco-2 cells). The effects observed on the basolateral 
chamber where the THP-1 cells reside are mediated 
indirectly by signals produced by the Caco-2 cells and/or 
by the transport of micro- and macro-molecules.
Briefly, the apical compartment containing Caco-
2 cells was filled with sterile-filtered (0.22 μm) colonic 
table 2: overview of treatment stages with 5-fluorouracil and vancomycin in the sHIMe
Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 Week 8
Stabilization Stabilization Control Control Treatment 
5-FU/vancomycin
Recovery 
from 
treatment
Recovery 
from 
treatment
Recovery 
from 
treatment
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SHIME suspensions (diluted 1:5 (v/v) in Caco-2 complete 
medium). Cells were also treated apically with 12 mM 
Sodium butyrate (NaB) (Sigma-Aldrich) as a positive 
control in experiments establishing the system. The 
basolateral compartment containing THP1 cells was filled 
with Caco-2 complete medium. Cells were also exposed 
to Caco-2 complete medium in both chambers in control 
experiments. Cells were treated for 24 h, at which time 
the basolateral supernatant was discarded and THP-1 cells 
were stimulated with Caco-2 complete medium containing 
500 ng/mL of ultrapure LPS (Escherichia coli K12, 
InvivoGen). Cells were also stimulated at the basolateral 
side with LPS in combination with 1 μM hydrocortisone 
(HC) (Sigma-Aldrich) and medium without LPS (LPS-) 
in control experiments. Cultures were incubated at 37 
degrees Celcius in a humidified atmosphere of air/CO2 
(95:5, v/v). After 6 h of LPS stimulation, the basolateral 
supernatants were collected for cytokine measurement 
(human IL-6 and IL-10) by Luminex. multiplex 
(Affymetrix-eBioscience) according to the manufacturers’ 
instructions. All treatments were done in triplicate.
statistics
To evaluate the difference between the treatment 
sample and its respective control sample within each 
SHIME, a two-way ANOVA with Sidak’s multiple 
comparisons test was performed. These results are 
presented on the graphs. To evaluate the difference 
between the SHIMES (CUR and PREV) compared to the 
CTRL SHIME within each colon compartment for both the 
control and the treatment phase, a two-way ANOVA with 
Dunnett’s multiple comparisons test was performed. These 
results are presented in the figures where (*) represents 
p < 0.05. All statistics were performed using GraphPad 
Prism version 7.02 for Windows (GraphPad Software, San 
Diego, CA, USA).
For the analysis of the cytokines IL-6 and IL-10, 
statistical significance was calculated between the 
different SHIMES (CUR and PREV) compared to the 
CTRL SHIME using two-way ANOVA with Dunnett’s 
multiple comparisons test was performed. Results were 
considered significant if p < 0.05.
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